{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:33Z","timestamp":1772165673579,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09861-5","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T05:02:35Z","timestamp":1727413355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants"],"prefix":"10.1186","volume":"24","author":[{"given":"Mathieu","family":"Chalouni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Loubet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Lhomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laetitia","family":"Ninove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Barrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryvonne","family":"Hourmant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9rome","family":"de Seze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Laville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Laviolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Daniel","family":"Leli\u00e8vre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie Nguyen","family":"Quoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Thiebaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Francois","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Vrtovsnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Circosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Barquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Gharib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Tartour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Parfait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"de Lamballerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Launay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Wittkop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the ANRS0001S COV-POPART study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"10269","key":"9861_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Lond Engl. 2021;397(10269):99\u2013111.","journal-title":"Lancet Lond Engl"},{"issue":"27","key":"9861_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"1","key":"9861_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35\u201345.","journal-title":"JAMA"},{"key":"9861_CR4","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Avis n\u00b0 2022.0004\/AC\/SESPEV du 13 janvier 2022 du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 relatif \u00e0 la place du vaccin Janssen en seconde dose et en dose de rappel dans la strat\u00e9gie de vaccination contre la Covid-19. Available from: https:\/\/www.has-sante.fr\/jcms\/p_3309607\/fr\/avis-n-2022-0004\/ac\/sespev-du-13-janvier-2022-du-college-de-la-haute-autorite-de-sante-relatif-a-la-place-du-vaccin-janssen-en-seconde-dose-et-en-dose-de-rappel-dans-la-strategie-de-vaccination-contre-la-covid-19. Cited 2023 Jan 17."},{"issue":"8","key":"9861_CR5","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41591-021-01435-1","volume":"27","author":"P Loubet","year":"2021","unstructured":"Loubet P, Wittkop L, Tartour E, Parfait B, Barrou B, Blay JY, et al. A French cohort for assessing COVID-19 vaccine responses in specific populations. Nat Med. 2021;27(8):1319\u201321.","journal-title":"Nat Med"},{"key":"9861_CR6","doi-asserted-by":"crossref","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA et al. BNT162b2 mRNA Covid-19 vaccine in a Nationwide Mass Vaccination setting. N Engl J Med. 2021;384(15):1412\u201323.","DOI":"10.1056\/NEJMoa2101765"},{"issue":"10287","key":"9861_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet Lond Engl. 2021;397(10287):1819\u201329.","journal-title":"Lancet Lond Engl"},{"issue":"11","key":"9861_CR8","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032\u201340.","journal-title":"Nat Med"},{"issue":"7847","key":"9861_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630\u20134.","journal-title":"Nature"},{"issue":"7","key":"9861_CR10","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205\u201311.","journal-title":"Nat Med"},{"issue":"32","key":"9861_CR11","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423\u20138.","journal-title":"Vaccine"},{"issue":"6576","key":"9861_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43\u201350.","journal-title":"Science"},{"issue":"6561","key":"9861_CR13","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.abj4176","volume":"373","author":"A Pegu","year":"2021","unstructured":"Pegu A, O\u2019Connell SE, Schmidt SD, O\u2019Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021;373(6561):1372\u20137.","journal-title":"Science"},{"issue":"10323","key":"9861_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0140-6736(22)00017-4","volume":"399","author":"N Wolter","year":"2022","unstructured":"Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet Lond Engl. 2022;399(10323):437\u201346.","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"9861_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1001\/jama.2021.24868","volume":"327","author":"C Maslo","year":"2022","unstructured":"Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron Wave compared with previous waves. JAMA. 2022;327(6):583\u20134.","journal-title":"JAMA"},{"issue":"16","key":"9861_CR16","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","volume":"5","author":"C Perry","year":"2021","unstructured":"Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-hodgkin lymphoma. Blood Adv. 2021;5(16):3053\u201361.","journal-title":"Blood Adv"},{"issue":"13","key":"9861_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMc2111462","volume":"385","author":"VG Hall","year":"2021","unstructured":"Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244\u20136.","journal-title":"N Engl J Med"},{"issue":"1","key":"9861_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev. 2022;310(1):6\u201326.","journal-title":"Immunol Rev"},{"issue":"22","key":"9861_CR19","first-page":"00522","volume":"S1198-743X","author":"P Loubet","year":"2022","unstructured":"Loubet P, Wittkop L, Ninove L, Chalouni M, Barrou B, Blay JY, et al. One-month humoral response following two or three doses of mRNA Covid-19 vaccines as primary vaccination in specific populations in France: first results from the ANRS0001S COV-POPART cohort. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;S1198-743X(22):00522\u20135.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"issue":"30","key":"9861_CR20","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381\u201397.","journal-title":"Stat Med"},{"issue":"1","key":"9861_CR21","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KGM Moons","year":"2015","unstructured":"Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1-73.","journal-title":"Ann Intern Med"},{"issue":"5","key":"9861_CR22","doi-asserted-by":"publisher","first-page":"e35311","DOI":"10.2196\/35311","volume":"8","author":"C Liu","year":"2022","unstructured":"Liu C, Lee J, Ta C, Soroush A, Rogers JR, Kim JH, et al. Risk factors associated with SARS-CoV-2 breakthrough infections in fully mRNA-Vaccinated individuals: retrospective analysis. JMIR Public Health Surveill. 2022;8(5):e35311.","journal-title":"JMIR Public Health Surveill"},{"key":"9861_CR23","doi-asserted-by":"publisher","first-page":"856532","DOI":"10.3389\/fpubh.2022.856532","volume":"10","author":"JM Yamal","year":"2022","unstructured":"Yamal JM, Appana S, Wang M, Leon-Novelo L, Bakota E, Ye Y, et al. Trends and correlates of breakthrough infections with SARS-CoV-2. Front Public Health. 2022;10:856532.","journal-title":"Front Public Health"},{"issue":"2","key":"9861_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41574-021-00608-9","volume":"18","author":"N Stefan","year":"2022","unstructured":"Stefan N. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Nat Rev Endocrinol. 2022;18(2):75\u20136.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"9861_CR25","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41467-022-32265-5","volume":"13","author":"RW Aldridge","year":"2022","unstructured":"Aldridge RW, Yavlinsky A, Nguyen V, Eyre MT, Shrotri M, Navaratnam AMD, et al. SARS-CoV-2 antibodies and breakthrough infections in the virus watch cohort. Nat Commun. 2022;13(1):4869.","journal-title":"Nat Commun"},{"issue":"1","key":"9861_CR26","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52-61.","journal-title":"Lancet Microbe"},{"issue":"12","key":"9861_CR27","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41564-022-01262-1","volume":"7","author":"Y Fong","year":"2022","unstructured":"Fong Y, McDermott AB, Benkeser D, Roels S, Stieh DJ, Vandebosch A, et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat Microbiol. 2022;7(12):1996\u20132010.","journal-title":"Nat Microbiol"},{"issue":"9","key":"9861_CR28","doi-asserted-by":"publisher","first-page":"107621","DOI":"10.1016\/j.isci.2023.107621","volume":"26","author":"EAM Baerends","year":"2023","unstructured":"Baerends EAM, Hvidt AK, Reekie J, S\u00f8gaard OS, St\u00e6rke NB, Raben D, et al. SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection. iScience. 2023;26(9):107621.","journal-title":"iScience"},{"issue":"1","key":"9861_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12916-024-03304-3","volume":"22","author":"C Mart\u00edn P\u00e9rez","year":"2024","unstructured":"Mart\u00edn P\u00e9rez C, Aguilar R, Jim\u00e9nez A, Salmer\u00f3n G, Canyelles M, Rubio R, et al. Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination. BMC Med. 2024;22(1):103.","journal-title":"BMC Med"},{"issue":"1","key":"9861_CR30","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41467-023-36984-1","volume":"14","author":"U Marking","year":"2023","unstructured":"Marking U, Havervall S, Norin NG, Bladh O, Christ W, Gordon M, et al. Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. Nat Commun. 2023;14(1):1577.","journal-title":"Nat Commun"},{"issue":"5","key":"9861_CR31","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41591-022-01739-w","volume":"28","author":"L Chu","year":"2022","unstructured":"Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med. 2022;28(5):1042\u20139.","journal-title":"Nat Med"},{"issue":"5","key":"9861_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jinf.2022.09.004","volume":"85","author":"A Atti","year":"2022","unstructured":"Atti A, Insalata F, Carr EJ, Otter AD, Castillo-Olivares J, Wu M, et al. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: a nested case-control within the SIREN study. J Infect. 2022;85(5):545\u201356.","journal-title":"J Infect"},{"key":"9861_CR33","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.7326\/M22-1300","volume":"175","author":"D Follmann","year":"2022","unstructured":"Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 Vaccine efficacy clinical trial. Ann Intern Med. 2022;175:1258\u201365.","journal-title":"Ann Intern Med."},{"key":"9861_CR34","doi-asserted-by":"publisher","first-page":"104880","DOI":"10.1016\/j.antiviral.2020.104880","volume":"181","author":"P Gallian","year":"2020","unstructured":"Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res. 2020;181:104880.","journal-title":"Antiviral Res"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09861-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09861-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09861-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T17:01:48Z","timestamp":1727456508000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09861-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9861"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09861-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4510677\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from each participant before enrolment taking into account the GDPR (European Union General Data Protection Regulation) requirements. The protocol (N\u00b0 EudraCT \/ ID-RCB: 2021-A00348-33) was conducted in accordance with the Declaration of Helsinki and French law for research involving human subjects (known as Loi Jard\u00e9). The protocol was approved by Ethics Committees: the committee for protection of participants engaged in research \u201cCPP Nord-Ouest IV\u201d (file number: 21.02.12.47147) and the French national data protection authority \u201cCNIL\u201d (Commission Nationale Informatique et Libert\u00e9, authorization number 921111v1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PL has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astrazeneca, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Pfizer, Sanofi Pasteur and Support for attending meetings and\/or travel from Pfizer, Sanofi Pasteur. JM has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Biogen, BMS, Boerhinger Ingelheim, Galapagos, GSK, Fresenius Kabi, Lilly, Mylan, Novartis, Pfizer, Sanofi and grants outside the submitted work from Lilly, Novartis. JPS has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer and Astrazeneca. OL has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi Pasteur; Pfizer, Janssen and, non-financial support from Sanofi Pasteur; Pfizer, Janssen, GlaxoSmithKline and grant from GlaxoSmithKline. The other authors declare having no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1049"}}